A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
复制标题
DOI：
10.1517/14712590903446921
复制
发表时间：
2009-12-01
影响因子：
4.6
通讯作者：
Fishman, Mayer
中科院分区：
文献类型：
--
作者：
Fishman, Mayer
背景：Northwest Therapeutics的dcvax -前列腺由装载前列腺特异性膜抗原（PSMA）肽的自体树突状细胞（dc）组成，静脉注射。十年前的I-II期试验显示了一些患者的临床益处和免疫反应。最近，使用类似DC平台的DCvax脑产品显示出令人鼓舞的I-II期结果，而前列腺酸性磷酸酶（PAP）导向的DC免疫疗法sipleucel-T具有积极的III期结果。目的：讨论一种新的免疫疗法可能引入的临床环境特点，在前列腺癌治疗方法不断发展的背景下，完善对dcvax -前列腺的看法。综述了psma定向治疗和免疫抗癌技术，并对dcvax -前列腺癌的临床和免疫学相关检测进行了讨论。方法：临床和临床前数据来自同行评审的文献，会议记录和制造商提供的信息。结论：dcvax -前列腺具有令人鼓舞的早期试验结果，但开发和测试已经停滞。随着对患者选择抗癌免疫应答能力的更详细了解，免疫相关物的定量，以及不断变化的市场发展，考虑一种耐受性良好、psma导向的自体树突状细胞治疗产品是很有吸引力的。如果要找到相关的临床应用，进一步的临床试验发展是必要的。
Background: Northwest Therapeutics' DCvax-prostate consists of autologous dendritic cells (DCs) loaded with prostate-specific membrane antigen (PSMA) peptides, administered intravenously. Phase I-II testing, a decade ago, showed clinical benefit and immunological response in some patients. More recently DCvax brain, a product using a similar DC platform showed encouraging Phase I-II results and sipleucel-T, a prostatic acid phosphatase (PAP)-directed DC immunotherapy had positive Phase III results. Objective: Features of the clinical setting into which a new immunotherapy could be introduced are discussed, to refine a perspective on DCvax-prostate in the context of evolving prostate cancer therapeutics. PSMA-directed therapeutics and immune anticancer technologies are reviewed, and the clinical and immunological correlative testing of DCvax-prostate is discussed. Methods: Clinical and preclinical data from peer-reviewed literature, meetings proceedings and manufacturer-provided information are considered. Conclusion: DCvax-prostate had encouraging early-phase trial results, but development and testing had stalled. As a more detailed understanding of patient-selection for capacity for anticancer immune response, the quantitation of immunological correlates, and the changing marketplace develop, it is appealing to consider a well tolerated, PSMA-directed autologous dendritic cell therapeutic product. Further clinical trial development of DCvax-prostate is warranted, and required if it is to find a relevant clinical application.